The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium facilitating the clinical implementation of pharmacogenetic tests for improved patient care.
CPIC’s goal is to translate genetic laboratory test results into actionable prescribing decisions for affected drugs by creating, curating, and posting the latest information for free. This peer-reviewed and evidence-based database would be updatable and contain detailed gene/drug clinical practice guidelines.
The Pharmacogenomics knowledge base (PharmGKB) is a National Institute of Health (NIH)-funded resource that provides information about how human genetic variation affects response to medications. PharmGKB collects, curates, and disseminates knowledge about clinically actionable gene-drug associations and genotype-phenotype relationships.
Table of PGx biomarkers in drug labeling, approved by the FDA
The U.S. Food and Drug Administration (FDA) maintains a list of labels containing PGx information called the “Table of PGx Biomarkers in Drug Labels”. Drug labeling may contain information on genomic biomarkers and can describe drug-associated clinical response variability, risk for adverse events, genotype-specific dosing, and mechanisms of drug action., Moreover, clinical trial design features, polymorphic drug targets, and disposition genes may also be described.